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Summary The biodistribution of radiolabelled SWAl 1, a mouse monoclonal antibody recognising the cluster
w4 group antigen associated with small cell lung cancer (SCLC) was studied in patients with SCLC. Five
patients were injected intravenously with approximately 5 mCi of '31I conjugated to I mg of SWAII. The
half-life of the radiolabel in blood was short but there was a prolonged second phase of clearance with a
half-life of about 40 h. Tumour was detected by gamma camera imaging two patients. However, most of the
whole body radioactivity was located in the bone marrow. At least 35% of the radioactivity in blood 18 h
after injection was bound to circulating granulocytes and this probably accounted for the unusual biodistri-
bution of the radiolabel in man. This study shows that the biodistribution of radiolabelled SWA 11 in man
differs from human tumour xenograft models and that the antibody in unsuitable for targeting therapy to
SCLC in man.
Small cell lung cancer (SCLC) is a rapidly proliferating
tumour which spreads early in the course of its growth. The
tumour is extremely chemosensitive and approximately half
of all patients enter a complete clinical remission after com-
bination chemotherapy (Feld et al., 1987). However, virtually
all patients relapse due to the emergence of drug resistant
disease. New therapies are needed to improve the outcome of
this disease as only 3% of patients are alive at 7 years
(Souhami & Law, 1990).
One approach is to use monoclonal antitumour antibody
conjugates with sufficient selectivity for tumours and a high
potency to eradicate residual malignant cells. Antibody
targeted radiation has already shown promise in the treat-
ment of lymphomas and hepatocellular cancer where quite
large doses of radiation have been delivered (Lenhard et al.,
1985, Order et al., 1985, Press et al., 1989). Radioim-
munotherapy is likely to be most successful in patients with
small tumours, as studies in animal xenograft tumours have
shown that antibody uptake as a proportion of the inejcted
dose is greatest in small tumours (Pedley et al., 1987). SCLC
is ideally suited to antibody targeted radiation because of its
radiosensitivity and the small size of residual tumour after
chemotherapy.
The antibody SWAI1 recognises a glycoprotein on the
surface of SCLC tumours. The antigen belongs to the cluster
w4 group defined by the International Workshops on Small
Cell Lung Cancer Antigens (Souhami et al., 1988, Souhami
et al., 1991). SWAI1 binds to some adenocarcinomas, car-
cinoid tumours and ductal epithelia. The antibody also binds
weakly to a subpopulation of human granulocytes (Smith et
al., 1989). Radiolabelled SWAl1 has been shown to localise
specifically in SCLC tumours growing as xenografts in nude
mice and intravenous injections of therapeutic doses of 131I
SWAl1 have eradicated SCLC xenografts in mice (Smith et
al., 1991, Smith et al., 1989). SWA 11 has also shown promise
as an immunotoxin (Wawrzynczak et al., 1991). These results
provide a rationale for clinical studies to investigate whether
radiolabelled SWAI1 localises in SCLC tumours.
Methods
Antibody
SWAI1, a mouse IgG2a monoclonal antibody was produced
as previously described (Smith et al., 1989). Antibody for
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clinical studies was produced in hollow fibre culture and
purified by protein A Sepharose, ion-exchange chromato-
graphy and Superdex 200 gel filtration. The antibody was
prepared for clinical use according to the guidelines estab-
lished by the Operation Manual for the Control and Produc-
tion of antibodies and Conjugates (Operation manual, 1986).
One milligram of antibody was conjugated to approximately
5 mCi of "'1I using chloramine T. Over 90% of the radioac-
tivity was incorporated into protein and a cell binding assay
using a human SCLC cell line, UCH1O showed that there
was preservation of antigen binding after radiolabelling. Gel
chromatography (sephadex S200) showed that the radio-
labelled antibody was free of aggregates.
Administration
Oral potassium iodide, and potassium perchlorate were given
to block uptake of radioactivity in the thyroid gland. An
intradermal injection of 2 to 4fig of radiolabelled antibody
was given to test for hypersensitivity before 31I SWAl1 was
injected intravenously over 5 min.
Venous blood samples were drawn immediately following
injection from the contralateral arm, and at 24, 48 and 72 h
after injection. Whole blood radioactivity was counted in a
gamma counter. Anterior and posterior whole body images
of patients were acquired at 24, 48 and 72 h or 96 h after
injection ofthe radiolabelled antibody using an IGE Starcam
gamma camera fitted with a high energy collimator.
Results
Patients
Radiolabelled antibody was given to five patients with newly
diagnosed (2), relapsed (1) or persistent (2) small cell lung
cancer. All had tumour in the lung, one had a brain metas-
tasis, and one- had a subcutaneous deposit and metastases in
the liver and bone. None of the patients had a positive skin
reaction to a test dose of antibody or side effects following
the injection of the radioimmunoconjugate. There was no
evidence of haematological or biochemical toxicity following
administration of radiolabelled antibody.
Plasma clearance
The blood clearance of radioactivity was remarkably con-
stant in all five patients (Figure 1). There was a rapid
clearance of radiolabel during the first 20 to 24 h. By 25 h the
blood radioactivity fell to one quarter or less of the initial
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Whole blood clearance of 131-1 SWAl 1 Table I Uptake in a single patient (see text) expressed as a
percentage of total body activity determined from geometric means
of counts obtained from a 15 x 15 pixel anterior and posterior
gamma camera image
Organ % Uptake (48h) % Uptake (72h)
Tumour (left lung) 3.38 3.75
Bone marrow (axial skeleton) 43.63 43.06
Spleen 4.53 5.25
Liver 4.41 4.08
60
Hours
Figure 1 Whole blood clearance of radioactivity in five patients
following injection of "'I SWAl1. Results are expressed as a
percentage of the radioactivity in blood immediately following
injection of the radiolabelled antibody.
activity. This was followed by a second phase of clearance
with a half-life of about 40h.
Imaging
The distribution of '3'I SWAl1 was similar in all patients.
Planar imaging at 24 h rarely showed evidence of a cir-
culating pool of radioactivity. Tumour was identified in two
out of five patients. The example in Figure 2 shows that by
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Figure 2 Anterior (A) and posterior (P) gamma camera images
48 h after injection of I'lI SWAI 1 showing uptake of radioac-
tivity in a tumour (T) of the left lung, bone marrow and spleen
(S).
48 h the radiolabel had cleared from the circulation and there
was intense activity in the spine, pelvic bones and spleen. The
primary tumour in the left lung was clearly visible. However,
a large metastasis in the left cerebral hemisphere was not
seen. In this patient the radioactivity uptake ratio was 1.8 for
tumour to normal lung and 1.4 for tumour to heart 48 h
after injection of 13'I SWA11. The uptake of radioactivity in
the tissues as a percentage of the total body radioactivity is
shown in Table I. The maximum uptake of radioactivity in
the tumour was 3.75% of the total body activity 72 h after
injection of the antibody. However, 43.1% of the whole body
activity was in the bone marrow. A preparation of leuco-
cytes, 92% of which were neutrophils, was made from this
patient 18 h after injection of radiolabelled antibody. At least
35% of the radioactivity was associated with granulocytes.
This is likely to be an underestimate of the radioactivity as
not all leucocytes are separated from red cells duirng the
preparation of leucocytes.
In another patient the gamma camera images showed a
known soft tissue mass overlying the left scapula. This area
contained more radioactivity than the neighbouring lung but
less than the radioactivity in the liver and spleen. A 'Tc
methylene diphosphonate bone scan showed accumulation of
tracer in the soft tissue deposit, suggesting that in this case
localisation of radiolabelled antibody was nonspecific.
Discussion
The biodistribution of radioactivity following intravenous
injection of 13'I SWA 11 was similar in all patients. The
estimated blood half-life of "'lI SWAI during the first 24 h
was between 9 and 12 h, about half the value generally
observed following intravenous injection of intact murine
antibody in man. The antibody was not aggregated and it is
likely that the rapid removal of radiolabel from the circula-
tion were due to its uptake by the bone marrow and spleen
which was seen on the early gamma camera images. A study
of the distribution ofradioactivity in the blood of one patient
showed that a high proportion of radioactivity was
associated with granulocytes. It is likely that antibody
localised in areas rich in granulocytes and their precursors
and that the small amount of residual radiolabel bound to
circulating granulocytes accounted for the prolonged second
half-life of the radiolabel in blood.
Preclinical studies demonstrated that SWA 11 bound to
granulocytes, but with a much lower affinity than to SCLC
cells (Smith et al., 1989). We proceeded with a clinical study
as it was unclear whether the interaction of SWAl1 with
granulocytes would impair tumour targeting in man, and
because of the encouraging results of therapy with "3'I
SWAl1 in animals (Smith et al., 1991). Since starting the
clinical studies the gene for the cluster w4 antigen has been
cloned and it has been shown to be almost identical to the
CD24 molecule expressed on human granulocytes (Jackson et
al., 1992).
The disparity between the results of the distribution of
radiolabelled SWA 11 in man and mice illustrates some of the
limitations of xenograft studies. We suggest that in future
simple investigations in animals should be followed by a
clinical study, having first excluded any interaction of the
antitumour antibody with blood cells and tissue that it likely
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to be accessible to antibody in vivo. Guidelines for preparing
potential antitumour antibodies in patients have been clearly
defined (Operation Manual, 1986) and a method of rapid
clinical screening to investigate putative antitumour
antibodies is quite simple to establish.
Large quantities of the cluster w4 antigen are found in
SCLC cells but the granulocyte mass is much greater than
that of the tumour. Therefore, despite a lower affinity of
SWA 11 for granulocytes the antibody is not useful for
targeted therapy of SCLC. However, the high concentration
of radioactivity in areas rich in white cells suggests that
SWAII might have a useful role in localising sites of infec-
tion in patients with unexplained fever.
This investigation was performed under the auspices of the phase I/1I
trial committee of the Cancer Research Campaign. We would like to
thank Prof. R. Begent and colleagues at the Royal Free Hospital
Medical School London for performing some of the preclinical tox-
icity tests on SWAl1.
References
FELD, R., EVANS, W.K., COY, P., HODSON, I., MACDONALD, A.S.,
OSOBA, D., PAYNE, D., SHELLEY, W. & PATER, J.L. (1987).
Canadian Multicentre randomised trial comparing sequential and
alternating administration of two non-cross resistant
chemotherapy combinations in patients with limited small cell
carcinoma of the lung. J. Clin. Oncol., 5, 1401-1409.
JACKSON, D., WAIBEL, R., WEBER, E, BELL, J. & STAHEL, R.A.
(1992). CD24, a signal-transducing molecule expressed on human
B cells, is a major surface antigen on small cell lung carcinomas.
Cancer Res., 52, 5264-5270.
LENHARD, R.E., ORDER, S.E., SPUNBERG, J.J., ASBELL, S.O. &
LEIBEL, S.A. (1985). Isotopic immunoglobulin: a new systemic
therapy for advanced Hodgkin's disease. J. Clin. Oncol., 3,
1296-1300.
OPERATION MANUAL FOR CONTROL OF PRODUCTION, PRE-
CLINICAL TOXICOLOTY AND PHASE 1 TRIALS OF ANTI
TUMOUR ANTIBODIES AND DRUG ANTIBODY CONJUGATES
(1986). Br. J. Cancer, 54, 557-568.
ORDER, S.E., STILLWAGON, G.B., KLEIN, J.L., LEICHNER, P.K.,
SIEGELMAN, S.S., FISHMAN, E.K., ETTINGER, D.S., HAULK, T.,
KOPHER, K., FINNEY, K., SURDYKE, M., SELF, S. & LEIBEL, S.
(1985). Iodine 131 antiferritin, a new treatment modality in
hepatoma: A Radiation Oncology Group study. J. Clin. Oncol.,
3, 1573-1582.
PEDLEY, R.B., BODEN, J., KEEP, P.A., HARWOOD, P.J., GREEN, A.J.
& ROGERS, G.T. (1987). Relationship between tumour size and
uptake of radiolabelled anti-CEA in a colon tumour xenograft.
Eur. J. Nucl. Med., 13, 197-202.
PRESS, O.W., EARY, J.F., BADGER, C.C., MARTIN, P.J., APPELBAUM,
F.R., LEVY, R., MILLER, R., BROWN, S., NELP, W.B., KROHN,
K.A., FISHER, D., DESANTES, K., PORTER, B., KIDD, P.,
THOMAS, E.D. & BERNSTEIN, I.D. (1989). Treatment of refrac-
tory non-Hodgkin's lymphoma with radiolabelled MB-1 (anti-
CD37) antibody. J. Clin. Oncol., 7, 1027-1038.
SMITH, A., WAIBEL, R., WESTERA, G., MARTIN, A., ZIMMERMAN,
A.T. & STAHEL, R.A. (1989). Immunolocalisation and imaging of
small cell cancer xenografts by the IgG2a monoclonal antibody
SWAll. Br. J. Cancer, 59, 174-178.
SMITH, A., WAIBEL, R. & STAHEL, R.A. (1991). Selective
immunotherapy of small cell cancer xenografts using '311-labelled
SWAI1 antibody. Br. J. Cancer, 64, 263-266.
SOUHAMI, R.L., BEVERLEY, P.C.L. & BOBROW, L.G. (1988). The
antigens of small cell lung cancer. First International Workshop.
Lancet, i, 325-326.
SOUHAMI, R.L. & LAW, K. (1990). Longevity in small cell lung
cancer. A report to Lung Cancer subcommittee of the United
Kingdom Committee for Cancer Research. Br. J. Cancer, 61,
584-589.
SOUHAMI, R.L., BEVERLEY, P.C.L., BOBROW, L.G. & LEDERMANN,
J.A. (1991). The antigens of Lung Cancer. Results of the Second
International Workshop on Lung Cancer Antigens. J. Natl
Cancer Inst., 83, 609-612.
WAWRZYNCZAK, E.J., DERBYSHIRE, E.J., HENRY, R.V., PARNELL,
G.D., SMITH, A., WAIBEL, R. & STAHEL, R.A. (1991). Cytotoxic
activity of ricin A chain immunotoxins recognising cluster 1, w4
and 5a antigens associated with human small cell lung cancer. Br.
J. Cancer, 63 Suppl XIV, 71-73.